KALV News and Press, KalVista Pharmaceuticals Inc. From 10/14/22

Summary KalVista intends to provide best-in-class therapies, both for acute on-demand and prophylaxis treatment, to fundamentally change the way HAE is treated. Its lead drug Sebetralstat is currently being investigated in a Phase 3 study and top-line results are expected in the s...

Summary With KalVista's KVD824 off the market, Orladeyo will enjoy a stronger market presence since it was the first oral treatment for the HAE disorder after its approval in December 2020. BioCryst announced at the end of August 2022 that the FDA had granted orphan drug designati...

– Data examines patient perspectives on treatment outcome measures used in phase 3 KONFIDENT trial of sebetralstat - – Additional data show the impact of HAE on mental health, daily activities, and quality of life of people living with HAE - KalVista Ph...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips KalVista Pharmaceuticals (NASDAQ: KALV ) is trending on popular financial social media right now, but it’s not good news. Reportedly, there were safety-related concerns over KalVista’s clinical study o...

KalVista Pharmaceuticals ( NASDAQ: KALV ) said it terminated a phase 2 trial of oral drug KVD824 to prevent ((hereditary angioedema)) attacks after safety concerns related to elevated levels of a liver enzyme were seen. The study, dubbed KOMPLETE, had...

- Safety signals observed will not yield targeted product profile – - No impact on Sebetralstat expected safety profile or Phase 3 KONFIDENT trial – - Oral Factor XIIa program to become primary focus for HAE prophylaxis - KalVista Pharmaceutical...

- Data provides patient perspectives on optimal treatment outcomes and quality-of-life challenges for people living with HAE - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization ...

KalVista Pharmaceticals press release ( NASDAQ: KALV ): Q1 GAAP EPS of -$0.94. Cash, cash equivalents and marketable securities were $142.1 million as of July 31, 2022, compared to $166.2 million as of April 30, 2022. The decrease in the net cash and marketable securit...

- NDA-supporting study extension provides additional two years of treatment with sebetralstat to assess long-term safety and tolerability in HAE patients - - Subtrial will assess sebetralstat profile in adolescent patients - KalVista Pharmaceuticals, Inc. (NA...

The shares of KalVista Pharmaceuticals, Inc. ( NASDAQ: KALV ) reached the highest level since March on Monday after Pharvaris N.V. ( PHVS ), its Dutch rival in hereditary angioedema (HAE), announced an FDA clinical hold on its lead asset, PHA121. An oral bradykinin B2-...